Pepgen announces clearance of cta by uk medicines & healthcare products regulatory agency to begin connect2-edo51, a phase 2 clinical trial designed to support potential accelerated approval of pgn-edo51 for the treatment of duchenne muscular dystrophy

Boston, march 04, 2024 (globe newswire) -- pepgen inc. (nasdaq: pepg), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that the uk medicines & healthcare products regulatory agency (mhra) has authorized its clinical trial application (cta) to initiate the connect2-edo51 phase 2 clinical trial of pgn-edo51 in patients with duchenne muscular dystrophy (dmd) amenable to an exon 51-skipping approach.
PEPG Ratings Summary
PEPG Quant Ranking